News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Concordia Healthcare Corp (CXR.TO) Closes $67.6 Million Bought Deal Financing


3/11/2014 6:46:05 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Concordia Healthcare Corp. closes $67.6 million bought deal financing

TORONTO , March 11, 2014 /CNW/ - Concordia Healthcare Corp. ("Concordia") (CXR.TO), is pleased to announce that it has closed its previously announced short form prospectus offering, on a "bought deal" basis, of 5,750,000 common shares (the "Common Shares") of Concordia , which includes the exercise by the Underwriters (as defined below) of an over-allotment option of 15%, for aggregate gross proceeds of $67,562,500 (the "Offering"). The Offering was completed at a price per Common Share of $11.75 by a syndicate of underwriters co-led by GMP Securities L.P. and Canaccord Genuity Corp. and including Barclays Capital Canada Inc., Beacon Securities Limited and Cormark Securities Inc.

About Concordia

Concordia is a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs and medical devices for the diabetic population. The company's legacy pharmaceutical business consists of an ADHD-treatment drug, Kapvay® (clonidine extended release tablets), Ulesfia® (benzyl alcohol) Lotion a Head Lice Treatment, and an Asthma-related medication, Orapred ODT® (prednisolone sodium phosphate orally disintegrating tablets). Concordia's Specialty Healthcare Distribution (SHD) division (Complete Medical Homecare) distributes medical supplies targeting diabetes and related conditions. Concordia's orphan division, Pinnacle, markets Photofrin® in the United States .

Concordia operates out of facilities in Oakville, Ontario , Lenexa, Kansas (near Kansas City, Missouri ), Bannockburn , (near Chicago ), Illinois and Bridgetown, Barbados .

SOURCE Concordia Healthcare Corp.

Contact:

please visit www.concordiarx.com or contact:

Kristen Van Vogt
TMX Equicom
416-815-0700 x 244
kvanvogt@tmxequicom.com

Adam Peeler
TMX Equicom
416-815-0700 x 225
apeeler@tmxequicom.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES